Publication Alert: T1D Screening Consensus Guidance is Here
New Publication Alert! Breakthrough T1D spearheaded a paper titled “International consensus guidance for general population screening for islet autoantibodies to diagnose early-stage type 1 diabetes” that was published in Diabetologia. This is an important step toward integrating general population screening for type 1 diabetes (T1D) into clinical practice globally. Read on to learn more about […]
2024 greatest T1D hits: A glance at this year’s achievements
While we look back on 2024, we can reflect upon the incredible progress we’ve made in advancing breakthroughs toward cures and improving everyday life with T1D. This wouldn’t have been possible without each and every one of you and your continued support of our mission as we drive toward cures for T1D. Here are the […]
Results Are Out: Tzield Benefits Newly Diagnosed Individuals
A new study published in the New England Journal of Medicine shows Tzield can preserve beta cell health in certain individuals recently diagnosed with T1D.
Top Type 1 Diabetes Advances of Fiscal Year 2023
Breakthrough T1D highlights the top type 1 diabetes advances we've seen during fiscal year 2023, including cures and life-improving therapies.
Targeting a New Hormone Helps to Prevent Type 1 Diabetes
A publication authored by Harvard University scientists has found that targeting a new hormone, FABP4, can enhance beta cell function and prevent T1D.
First-in-Human T1D Vaccine Trial Reports Positive Results
A first-in-human study of the coxsackie B vaccine—made by Breakthrough T1D-funded researchers Drs. Hyoty and Knip—reports positive results.
Teplizumab (the Therapy that Delays T1D By Nearly 3 Years) Isn’t Approved…Yet
The FDA issued a letter to Provention Bio for the use of teplizumab to delay T1D in at-risk individuals, meaning that it has not been approved at this time.
Artificial Intelligence Identifies T1D Risk Factors in Children
Breakthrough T1D and IBM Research have published their first paper, applying world-class computing power to identify factors leading to the onset of T1D in children.
T1D Doesn’t Discriminate: Know Your Risk with T1Detect
How Breakthrough T1D’s screening education and awareness program can help address health disparities experienced by underserved members of the T1D community.
FDA Advisory Committee Recommends that Teplizumab Receives Approval
An FDA Advisory Committee weighed the evidence, and the results were positive: They recommended that the FDA approve teplizumab for at-risk individuals.
